GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Net Cash per Share

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Net Cash per Share : $-0.13 (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Algernon Pharmaceuticals's Net Cash per Share for the quarter that ended in Nov. 2023 was $-0.13.

The historical rank and industry rank for Algernon Pharmaceuticals's Net Cash per Share or its related term are showing as below:

During the past 9 years, the highest Price-to-Net-Cash Ratio of Algernon Pharmaceuticals was 42.76. The lowest was 2.47. And the median was 7.85.

AGNPF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.92
* Ranked among companies with meaningful Price-to-Net-Cash only.

Algernon Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Algernon Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Net Cash per Share Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only -0.05 0.63 0.14 -0.08 -0.12

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.14 -0.10 -0.12 -0.13

Competitive Comparison of Algernon Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, Algernon Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Price-to-Net-Cash falls into.



Algernon Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Algernon Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Aug. 2023 is calculated as

Net Cash per Share (A: Aug. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.093-2.018-0)/15.7758
=-0.12

Algernon Pharmaceuticals's Net Cash per Share for the quarter that ended in Nov. 2023 is calculated as

Net Cash per Share (Q: Nov. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.054-2.144-0)/15.7758
=-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (OTCPK:AGNPF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Algernon Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.